| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 10.03% | Barclays | $142 → $142 | Maintains | Equal-Weight |
| 09/14/2023 | 14.68% | Cantor Fitzgerald | → $148 | Reiterates | Underweight → Underweight |
| 07/27/2023 | 18.56% | Wells Fargo | → $153 | Maintains | Equal-Weight |
| 07/27/2023 | 30.96% | Credit Suisse | $163 → $169 | Maintains | Outperform |
| 07/26/2023 | 20.11% | Stephens & Co. | → $155 | Reiterates | Equal-Weight → Equal-Weight |
| 07/11/2023 | 31.73% | Mizuho | $150 → $170 | Maintains | Buy |
| 06/02/2023 | 26.31% | B of A Securities | → $163 | Assumes | Neutral → Buy |
| 05/16/2023 | 7.71% | Goldman Sachs | $124 → $139 | Maintains | Sell |
| 05/16/2023 | 16.23% | Mizuho | $140 → $150 | Maintains | Buy |
| 05/08/2023 | 19.33% | TD Cowen | $138 → $154 | Maintains | Market Perform |
| 04/27/2023 | 27.86% | Citigroup | $150 → $165 | Maintains | Buy |
| 04/27/2023 | 12.36% | Stephens & Co. | $140 → $145 | Maintains | Equal-Weight |
| 04/27/2023 | 20.11% | Deutsche Bank | $145 → $155 | Maintains | Buy |
| 04/27/2023 | 17.78% | RBC Capital | $130 → $152 | Maintains | Sector Perform |
| 04/27/2023 | 26.31% | Credit Suisse | $153 → $163 | Maintains | Outperform |
| 04/25/2023 | 10.03% | Barclays | $132 → $142 | Upgrades | Underweight → Equal-Weight |
| 04/21/2023 | 10.81% | Cantor Fitzgerald | → $143 | Initiates Coverage On | → Underweight |
| 04/19/2023 | 3.06% | JP Morgan | → $133 | Initiates Coverage On | → Neutral |
| 03/06/2023 | 12.36% | Deutsche Bank | $168 → $145 | Maintains | Buy |
| 03/06/2023 | 8.49% | Mizuho | $144 → $140 | Maintains | Buy |
| 03/06/2023 | 6.94% | Wells Fargo | $154 → $138 | Maintains | Equal-Weight |
| 03/03/2023 | 18.56% | Credit Suisse | $157 → $153 | Maintains | Outperform |
| 03/01/2023 | 0.74% | RBC Capital | $114 → $130 | Maintains | Sector Perform |
| 03/01/2023 | 8.49% | Stephens & Co. | $155 → $140 | Maintains | Equal-Weight |
| 03/01/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 02/28/2023 | 20.11% | Stephens & Co. | → $155 | Reiterates | → Equal-Weight |
| 01/24/2023 | 29.41% | UBS | $113 → $167 | Upgrades | Sell → Neutral |
| 01/09/2023 | 2.29% | Barclays | $115 → $132 | Maintains | Underweight |
| 01/03/2023 | 19.33% | Wells Fargo | → $154 | Upgrades | Underweight → Equal-Weight |
| 12/16/2022 | 12.36% | B of A Securities | $120 → $145 | Upgrades | Underperform → Neutral |
| 12/14/2022 | 11.58% | Mizuho | $126 → $144 | Maintains | Buy |
| 11/25/2022 | 21.66% | Credit Suisse | $129 → $157 | Maintains | Outperform |
| 11/02/2022 | -2.36% | Mizuho | $121 → $126 | Maintains | Buy |
| 10/27/2022 | -11.66% | SVB Leerink | $98 → $114 | Maintains | Market Perform |
| 08/24/2022 | -10.89% | SVB Leerink | $111 → $115 | Maintains | Market Perform |
| 07/28/2022 | -13.99% | SVB Leerink | $103 → $111 | Maintains | Market Perform |
| 07/27/2022 | -11.66% | RBC Capital | $130 → $114 | Maintains | Sector Perform |
| 07/15/2022 | -20.19% | SVB Leerink | $108 → $103 | Maintains | Market Perform |
| 07/12/2022 | -14.76% | Goldman Sachs | $125 → $110 | Maintains | Sell |
| 07/06/2022 | -30.26% | BMO Capital | → $90 | Downgrades | Market Perform → Underperform |
| 07/01/2022 | 9.26% | Credit Suisse | $156 → $141 | Maintains | Outperform |
| 07/01/2022 | -6.24% | Mizuho | $153 → $121 | Maintains | Buy |
| 06/30/2022 | -16.31% | SVB Leerink | $132 → $108 | Maintains | Market Perform |
| 06/17/2022 | -10.89% | Loop Capital | → $115 | Initiates Coverage On | → Hold |
| 05/13/2022 | 2.29% | SVB Leerink | $139 → $132 | Maintains | Market Perform |
| 05/03/2022 | 18.56% | Mizuho | $164 → $153 | Maintains | Buy |
| 04/28/2022 | -8.56% | Wells Fargo | $139 → $118 | Maintains | Underweight |
| 04/27/2022 | 4.61% | Stephens & Co. | $150 → $135 | Maintains | Equal-Weight |
| 04/27/2022 | 22.43% | Credit Suisse | $172 → $158 | Maintains | Outperform |
| 04/27/2022 | 0.74% | RBC Capital | $149 → $130 | Maintains | Sector Perform |
| 03/29/2022 | 7.71% | Wells Fargo | → $139 | Initiates Coverage On | → Underweight |
| 03/07/2022 | 3.84% | UBS | $124 → $134 | Maintains | Sell |
| 03/03/2022 | 27.08% | Mizuho | $151 → $164 | Maintains | Buy |
| 02/28/2022 | — | Seaport Global | Downgrades | Buy → Neutral | |
| 02/28/2022 | 7.71% | SVB Leerink | $136 → $139 | Maintains | Market Perform |
| 01/07/2022 | 5.39% | SVB Leerink | $132 → $136 | Maintains | Market Perform |
| 12/21/2021 | 9.26% | Barclays | $160 → $141 | Maintains | Underweight |
| 10/29/2021 | 17.01% | Mizuho | $178 → $151 | Maintains | Buy |
| 10/27/2021 | 2.29% | SVB Leerink | $140 → $132 | Maintains | Market Perform |
| 09/27/2021 | 8.49% | SVB Leerink | → $140 | Initiates Coverage On | → Market Perform |
| 09/24/2021 | 5.39% | UBS | → $136 | Initiates Coverage On | → Sell |
| 09/08/2021 | 16.23% | Goldman Sachs | $155 → $150 | Downgrades | Neutral → Sell |
| 08/12/2021 | 20.88% | Barclays | $170 → $156 | Downgrades | Overweight → Underweight |
| 07/28/2021 | 43.36% | Deutsche Bank | $160 → $185 | Maintains | Buy |
| 07/27/2021 | 31.73% | Barclays | $160 → $170 | Maintains | Overweight |
| 07/09/2021 | 31.73% | Seaport Global | → $170 | Initiates Coverage On | → Buy |
| 06/10/2021 | 27.86% | RBC Capital | $160 → $165 | Downgrades | Outperform → Sector Perform |
| 04/28/2021 | 23.98% | RBC Capital | $150 → $160 | Maintains | Outperform |
| 04/19/2021 | 23.98% | Deutsche Bank | $145 → $160 | Maintains | Buy |
| 01/14/2021 | 23.98% | Barclays | → $160 | Maintains | Overweight |
| 01/05/2021 | 11.58% | B of A Securities | → $144 | Downgrades | Neutral → Underperform |
| 09/21/2020 | -10.89% | JP Morgan | $138 → $115 | Downgrades | Neutral → Underweight |
| 07/29/2020 | -9.34% | Piper Sandler | $113 → $117 | Maintains | Neutral |
| 07/29/2020 | 8.49% | Credit Suisse | $139 → $140 | Maintains | Outperform |
| 06/09/2020 | 6.94% | Barclays | → $138 | Upgrades | Equal-Weight → Overweight |
| 04/30/2020 | 3.06% | UBS | $150 → $133 | Maintains | Buy |
| 04/29/2020 | 4.61% | Deutsche Bank | $165 → $135 | Maintains | Buy |
| 04/28/2020 | -0.81% | Citigroup | $157 → $128 | Maintains | Buy |
| 04/23/2020 | -12.44% | Piper Sandler | $141 → $113 | Maintains | Neutral |
| 03/23/2020 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 03/02/2020 | 20.11% | JP Morgan | $164 → $155 | Maintains | Neutral |
| 02/28/2020 | 27.86% | Baird | $160 → $165 | Maintains | Outperform |
| 02/28/2020 | 16.23% | UBS | $158 → $150 | Maintains | Buy |
| 02/28/2020 | 17.01% | Stephens & Co. | $153 → $151 | Maintains | Equal-Weight |
| 12/20/2019 | 27.08% | JP Morgan | $159 → $164 | Maintains | Neutral |
| 10/28/2019 | 6.94% | Barclays | $145 → $138 | Maintains | Equal-Weight |
| 07/31/2019 | 13.13% | Morgan Stanley | $135 → $146 | Maintains | Equal-Weight |
| 04/17/2019 | 0.74% | Barclays | $136 → $130 | Maintains | Equal-Weight |
| 03/04/2019 | 24.76% | UBS | $156 → $161 | Maintains | Buy |
| 03/04/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/01/2019 | 23.98% | Deutsche Bank | $140 → $160 | Maintains | Buy |
| 03/01/2019 | 5.39% | Barclays | $130 → $136 | Maintains | Equal-Weight |
| 03/01/2019 | 16.23% | Wells Fargo | $147 → $150 | Maintains | Outperform |
| 03/01/2019 | 27.08% | Citigroup | $140 → $164 | Maintains | Buy |
| 02/28/2019 | 12.36% | Baird | $140 → $145 | Maintains | Outperform |
| 01/14/2019 | — | Stephens & Co. | Initiates Coverage On | → Equal-Weight | |
| 01/03/2019 | 8.49% | Deutsche Bank | → $140 | Initiates Coverage On | → Buy |
| 12/14/2018 | — | Goldman Sachs | Downgrades | Neutral → Sell | |
| 10/29/2018 | 0.74% | Morgan Stanley | $134 → $130 | Maintains | Equal-Weight |
| 10/29/2018 | 0.74% | Barclays | $135 → $130 | Maintains | Equal-Weight |
| 10/29/2018 | 8.49% | Citigroup | $145 → $140 | Maintains | Buy |
What is the target price for Universal Health Servs (UHS)?
The latest price target for Universal Health Servs (NYSE: UHS) was reported by Barclays on January 14, 2021. The analyst firm set a price target for $160.00 expecting UHS to rise to within 12 months (a possible 23.98% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Universal Health Servs (UHS)?
The latest analyst rating for Universal Health Servs (NYSE: UHS) was provided by Barclays, and Universal Health Servs maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Universal Health Servs (UHS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Universal Health Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Universal Health Servs was filed on January 14, 2021 so you should expect the next rating to be made available sometime around January 14, 2022.
Is the Analyst Rating Universal Health Servs (UHS) correct?
While ratings are subjective and will change, the latest Universal Health Servs (UHS) rating was a maintained with a price target of $0.00 to $160.00. The current price Universal Health Servs (UHS) is trading at is $129.05, which is within the analyst's predicted range.